Fulacimstat is primarily investigated for its potential therapeutic applications in the treatment of cardiovascular diseases. It functions as a selective inhibitor of chymase, an enzyme involved in the production of angiotensin II, which plays a key role in blood pressure regulation and vascular remodeling. By inhibiting chymase, Fulacimstat may help reduce the pathological effects of angiotensin II, such as hypertension, cardiac fibrosis, and heart failure. This makes it a promising candidate for managing conditions like chronic heart failure and hypertensive heart disease, particularly in patients who do not respond adequately to conventional therapies like ACE inhibitors or angiotensin receptor blockers. Ongoing research aims to further explore its efficacy and safety in clinical settings.